VC: Alimera land $30M in third round



Alimera land $30M in third round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Alimera Sciences
Atlanta, GA

$30M
Third

Existing investors

Alimera Sciences plans to use much of that money to grab a much bigger share of the future profits expected from its late-stage therapy for diabetic macular edema.

TxCell
France

$16.54M
Second

Auriga Partners, AXA Private Equity, Bioam Gestion, CDC Innovation and Seventure

TxCell, which develops therapies for autoimmune and chronic inflammatory diseases, will use the funding to progress its development programs on Crohn's disease, rheumatoid arthritis and a number of orphan diseases.

EyeGate
Waltham, MA

$15M
Third

Medicis Capital, Ventech, Innoven Partenaires and The Nexus Group

The company will use the funding to commence two Phase II clinical studies using the EyeGate II Delivery System and it's own formulation of a corticosteroid.

EnGene
Vancouver

$6.4M
First

Saad Investments Company

EnGene, which is developing a treatment for diabetes called GEMS-Insulin, announced today it has raised $6.4 million in a Series A financing. Release

Axial Biotech
Salt Lake City

$6M
Second

Johnson & Johnson Development Corporation, vSpring Capital and Ohio Biotech Group

Axial is advancing new technology in molecular diagnostics and motion preserving to develop a genetic prognostic test for Adolescent Idiopathic Scoliosis.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.